Stocks and Investing
Stocks and Investing
Mon, November 6, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Terence Flynn Upgraded (CCCC) to Hold and Decreased Target to $1 on, Nov 6th, 2023
Terence Flynn of Morgan Stanley, Upgraded "C4 Therapeutics, Inc." (CCCC) to Hold and Decreased Target from $3 to $1 on, Nov 6th, 2023.
Terence has made no other calls on CCCC in the last 4 months.
There are 3 other peers that have a rating on CCCC. Out of the 3 peers that are also analyzing CCCC, 1 agrees with Terence's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Chi Fong of "B of A Securities" Maintained at Hold with Decreased Target to $2 on, Monday, October 9th, 2023
These are the ratings of the 2 analyists that currently disagree with Terence
- Etzer Darout of "BMO Capital" Maintained at Buy with Decreased Target to $16 on, Friday, November 3rd, 2023
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $7 on, Thursday, November 2nd, 2023
Contributing Sources